bullish
Pharmaessentia Corp (6446 TT): First In-House Drug Approval in the U.S., More to Follow
582 Views25 Nov 2021 23:29
SUMMARY
- Pharmaessentia Corp (6446 TT) received FDA approval for its rare cancer drug, BESREMi, which has superior clinical efficacy over the existing standard of care.
- The drug has already been approved in 17 countries in EU, Taiwan, and South Korea. It is also being developed for several other indications, with license expected in next year.
- BESREMi’s continued success in the EU markets since its launch in 2019 has enhanced my conviction on the commercial accomplishment of BESREMi in the U.S.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Pharmaessentia Corp (6446 TT): Riding High Aided by Continued Strong Uptake of Besremi in US14 Nov 2022
- Pharmaessentia Corp (6446 TT): Key Marketed Drug Besremi Is Showing No Sign of Slow Down10 Aug 2022
- Pharmaessentia Corp (6446 TT): Key Drug Is Advancing Commercialization Globally05 May 2022
- Pharmaessentia Corp (6446 TT): First In-House Drug Approval in the U.S., More to Follow25 Nov 2021
x